Objectives: Anal cancer incidence is increasing among HIV-positive patients. No consensus currently exists for the screening of anal dysplasia. This study aimed at evaluating the feasibility and acceptability of anal self-sampling and assessing the prevalence of human papillomavirus (HPV) types among HIV-positive patients from Marseille University Hospitals. Methods: Between October 2013 and March 2014, during their regular visits for the monitoring of their HIV infection in an HIV outpatient clinical unit of Marseille University Hospitals, patients were asked to self-sample anal swabs for HPV detection. A specimen self-collection kit was provided. HPV detection and genotyping were performed using in-house protocols. The quality of self-sampling was assessed by concurrent cellular quantification in collected samples. Results: The acceptability rate of anal self-sampling was 91%, and 91% of the self-sampled specimens were appropriate for HPV screening. In addition, 76% of the samples were positive for HPV, including 54% of HPV types with oncogenic potential. Conclusions: This study indicates that HPV detection and typing through anal self-sampling is a valuable strategy to screen patients at high risk for anal cancer development. This could allow earlier management of anal lesions and related cancer in patients at high risk for HPV.

Keywords:
Human papillomavirus genotyping, Human papillomavirus, Anal cancer screening, Self-sampling, High-risk human papillomavirus types
1.
Arbyn M, Castellagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J: Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-2686.
2.
Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, Hillman RJ, Petoumenos K, Roberts J, Tabrizi SN, Templeton DJ, Grulich AE: Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012;13:487-500.
3.
Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, Nelson M, Gazzard B: HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004;37:1563-1565.
4.
Chiao EY, Known SE, Stier EA, Schrag D: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005;40:451-455.
5.
Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause MP: Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008;22:1203-1211.
6.
Heard I, Poizot-Martin I, Potard V, Etienney I, Crenn-Hebert C, Moore C, Touraine P, Cubie H, Costagliola D: Prevalence of and risk factors for anal oncogenic human papillomavirus infection among HIV-infected women in France in the combination antiretroviral therapy era. J Infect Dis 2016;213:455-461.
7.
Prise en charge des personnes vivant avec le VIH. Recommandations du groupe d'experts Rapport 2013. La Documentation Française. http://social-sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf.
8.
Vajdic CM, Van Leeuwen MT, Jin F, Prestage G, Medley G, Hillman RJ, Stevens MP, Botes LP, Zablotska I, Tabrizi N, Grulich AE: Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sex Transm Infect 2009;85:330-335.
9.
Damay A, Fabre J, Costes V, Didelot JM, Didelot MN, Boulle N, Segondy M: Human papillomavirus (HPV) prevalence and type distribution, and HPV-associated cytological abnormalities in anal specimens from men infected with HIV who have sex with men. J Med Virol 2010;82:592-596.
10.
Burd EM: Human papillomavirus laboratory testing: the changing paradigm. Clin Microbiol Rev 2016;29:291-318.
11.
Ortoski RA, Kell CS: Anal cancer and screening guidelines for human papillomavirus in men. J Am Osteopath Assoc 2011;111(suppl 2):S35-S43.
12.
Leeds IL, Fang SH: Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg 2016;8:41-51.
13.
Read TRH, Vodstrcil L, Grulich AE, Farmer C, Bradshaw CS, Chen MY, Tabrizi S, Hocking JS, Anderson J, Fairley CK: Acceptability of digital anal cancer screening examinations in HIV-positive homosexual men. HIV Med 2013;14:491-496.
14.
Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A: HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-86.
15.
Cranston RD, Darragh TM, Holly EA, Jay N, Berry JM, Da Costa M, Efird JT, Palefsky JM: Self-collected versus clinician-collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV-positive men. J Acquir Immune Defic Syndr 2004;36:915-920.
16.
Rosenberg JG, Dodge B, Van der Pol B, Reece M, Herbenick D, Fortenberry JD: Reactions to self-sampling for ano-rectal sexually transmitted infections among men who have sex with men: a qualitative study. Arch Sex Behav 2011;40:281-288.
17.
Ortiz AP, Alejandro N, Pérez CM, Otero Y, Soto-Salgado M, Palefsky JM, Tortolero-Luna G, Romaguera J: Acceptability of cervical and anal HPV self-sampling in a sample of Hispanic women in Puerto Rico. PR Health Sci J 2012;31:205-212.
18.
Chin-Hong PV, Berry JM, Cheng SC, Catania JA, Da Costa M, Darragh TM, Fishman F, Jay N, Pollack LM, Palefsky JM: Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med 2008;149:300-306.
19.
Tamalet C, Obry-Roguet V, Ressiot E, Bregigeon S, Del Grande J, Poizot-Martin I: Distribution of human papillomavirus genotypes, assessment of HPV16 and 18 viral load and anal related lesions in HIV positive patients: a cross-sectional analysis. J Med Virol 2014;86:419-425.
20.
Tamalet C, Richet H, Carcopino X, Henry M, Leretraite L, Heid P, Leandri FX, Sancho-Garnier H, Piana L: Testing for human papillomavirus and measurement of viral load of HPV16 and 18 in self-collected vaginal swabs of women who do not undergo cervical cytological screening in Southern France. J Med Virol 2010;882:1431-1497.
21.
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi E, Benbrahimi-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V: A review of human carcinogens. Part B: biological agents. Lancet Oncol 2009;10:321-322.
22.
Lampinen TM, Latulippe L, Van Niekerk D, Schilder AJ, Miller ML, Anema A, Hogg RS: Illustrated instructions for self-collection of anorectal swab specimens and their adequacy for cytological examination. Sex Transm Dis 2006a;33:6:386-388.
23.
Lampinen TM, Chan K, Anema A, Kornegay J, Hogg RS, Coutlée F: Self-screening for rectal sexually transmitted infections: human papillomavirus. Clin Infect Dis 2006;42:308-309.
24.
Ortiz AP, Romaguera J, Pérez C, Otero Y, Soto-Salgado M, Mendez K, Valle Y, Da Costa M, Suarez E, Palefsky J, Tortolero-Luna G: Human papillomavirus infection in women in Puerto Rico: agreement between physician-collected and self-collected anogenital specimens. J Low Genit Tract Dis 2013;17:210-224.
25.
Park IU, Palefsky JM: Evaluation and management of anal intra-epithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr Infect Dis Rep 2010;12:126-123.
26.
Palefsky JM, Holly EA, Hogeboom JC, Ralston ML, DaCosta MM, Botts R, Berry JM, Jay N, Darragh TM: Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:314-319.
27.
Burgos J, Curran A, Tallada N, Guelar A, Navarro J, Landolfi S, Villar J, Crespo M, Ribera E, Falco V: Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. AIDS 2015;29:695-702.
28.
de Pokomandy A, Rouleau D, Ghattas G, Trottier H, Vézina S, Coté, P, Macleod J, Allaire G, Hadjeres R, Franco EL, Coutlée F: HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 2011;52:1174-1181.
29.
Cachay ER, Mathews WC: Human papillomavirus, anal cancer, and screening considerations among HIV-infected individuals. AIDS Rev 2013;15:122-133.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.